Vaxcyte, Inc.
PCVXNASDAQHealthcare● Active
$46.33
$-1.03(-2.17%)
Market Cap$6.7B
P/E Ratio—
52W High$65
52W Low$29.08
Vaxcyte, Inc. (PCVX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PCVX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.79B | $0.48B | $0.33B | $0.17B | $0.08B |
| G&A Expenses | $0.13B | $0.09B | $0.06B | $0.04B | $0.03B |
| Total Operating Expenses | $0.92B | $0.57B | $0.47B | $0.23B | $0.10B |
| Operating Income | ($0.92B) | ($0.57B) | ($0.47B) | ($0.23B) | ($0.10B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.12B | $0.11B | $0.06B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.77B) | ($0.46B) | ($0.40B) | ($0.22B) | ($0.10B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.77B) | ($0.46B) | ($0.40B) | ($0.22B) | ($0.10B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
| Wtd Avg Shares | 0.14B | 0.12B | 0.10B | 0.06B | 0.05B |
| EBITDA | ($0.74B) | ($0.45B) | ($0.39B) | ($0.21B) | ($0.10B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Vaxcyte, Inc. data
About Vaxcyte, Inc. (PCVX) Income Statement
Vaxcyte, Inc. (PCVX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PCVX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.77B) — a net profit margin of —.
Frequently asked questions
PCVX · 4 questionsVaxcyte, Inc. (PCVX) reported revenue of $0.00B for 2025, down —% year-over-year.
PCVX revenuePCVX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08